Sitemap

Every indexable page on GLP-1 Price Index.

Comparisons

Compounded

Core

Cost

Glp1

Microdosing

Peptides

Reviews

Tools

/tools

SURMOUNT-1 — mean body-weight reduction by tirzepatide dose, 72 weeks

Jastreboff AM et al., N Engl J Med 2022 (NCT04184622), n=2,539. Dose-response is real: the effect rises with dose. These are FDA-APPROVED SUBCUTANEOUS INJECTION doses — they do not transfer to compounded, microdose or ODT products. Trial means are not individual promises.

How this works in practice

A policy that is not operationalised is decoration. Here is what ours actually changes about the pages you read.

Every price carries a status. We do not upgrade a price to Verified because another comparison site published it. Sites in this category contradict each other routinely — the dataset behind this site corrected a stored TrimRx figure of $259 that matched no current tier, and an Eden brand-Zepbound figure of $299 that was actually LillyDirect’s price rather than Eden’s real $1,399. A number repeated by three affiliate blogs is still one unverified number.

What each evidence label means, and what it does not
Label	Means	Example on this site
Provider Reported	We hold a dated capture, or the fact comes from a primary source (FDA, the manufacturer, CMS).	LillyDirect's $299 — taken from Eli Lilly's own pricing page.
Reported — pending verification	A provider or a third party reports it. We have not captured it ourselves.	Competitor pricing; every pharmacy relationship on this site.
Evaluation in progress	Verification pending. We are not asserting the fact at all.	Cancellation terms we could not obtain in writing.

Every medical claim traces to a primary source. FDA labels and orders for regulatory status; PubMed-indexed randomised trials for efficacy; ClinicalTrials.gov for trial design. Reddit and patient forums are never used as evidence of price, safety, efficacy or legitimacy. Animal research is never presented as proof of a human clinical effect. An affiliate comparison site is never primary evidence for anything.

Commercial relationships, and what they do not buy

Material relationshipMaterial relationship disclosure. GLP-1 Price Index is published by US Peptides Partners LLC. The publisher and certain principals have financial relationships with several of the providers listed on this site, and we may receive compensation when readers use certain links.

Relationships the publisher has confirmed to date are named on the ownership disclosure. Where a provider is not named there, that is because the publisher has not confirmed a relationship — it is not a statement that we have verified its absence. We would rather show you that gap than imply an independence we have not checked.

Compensation does not increase the price you pay, and does not permit any provider to purchase a verification status, alter a documented fact, remove a material limitation, change a ranking, or bypass our published editorial and medical-review standards.

What compensation does not do: it does not change a score, a rank, an inclusion decision, or a negative finding. Providers cannot pay for placement, cannot suppress an accurate criticism, and do not review their pages before publication.

Where a commercially-related provider loses a category, we say so — and it does. Found beats NexLife on 12-month-prepaid full-dose tirzepatide at $169. Brand Foundayo, an FDA-approved oral pill, beats both at $149. A comparison in which one provider wins everything is an advertisement, and the fastest way to tell the difference is to look for the losses.

Corrections, and our own record

We publish prices in a market that changes them constantly, and we will get things wrong. When we do, we correct the page, date the correction, and say what changed — we do not quietly edit a number and pretend it was always right. Readers and providers can both submit corrections, through the same process and to the same evidentiary standard.

Corrections we have already applied, against our own earlier publication:

Removed a set of provider prices (Embody $99, SkinnyRx $129, Yucca Health $146 and others) that we had sourced from a third-party comparison site and could not substantiate against any official pricing page.
Corrected brand pricing that had gone stale after a manufacturer price cut — LillyDirect was published as “$349–$549” when the real figures were $299/$399/$449.
Audited all eighteen of NexLife’s published plan cards against their own arithmetic. Sixteen reconcile. Two do not, and we publish the arithmetic rather than the marketing figure — in both cases making a provider we may have a relationship with look slightly worse than its own advertising.

Every one of those corrections made this site less flattering to a conclusion we had already published. That is the point of having a corrections policy at all.

The numbers behind this page

Three questions to ask before acting on this page

Every price quoted in this page comes from the programme's own pricing page and carries the date it was captured.

Ask in writing, before enrolling anywhere. Is the quoted figure the month-to-month rate, or does it require a prepaid term? Does it include every mandatory recurring fee, or is a membership billed separately? And which pharmacy fills the prescription — a 503A compounding pharmacy or a 503B outsourcing facility, and is it licensed to ship to your state?

A programme answering all three plainly has given you what you need to verify it without us. One answering none has also told you something. Neither outcome requires trusting a comparison site.

Reading the price against the market

What a longer horizon costs

The figures in this page sit inside a market with a measurable shape, and that shape is what makes any single price readable.

At the cheapest verified semaglutide rate of $119 a month (NexLife, 12-month plan), medication alone runs $1,428 a year, $4,284 over three and $7,140 over five. At the dearest, $299 a month, the same horizons are $3,588, $10,764 and $17,940.

Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops. The relevant question is what a sustainable course costs, not what a first year costs.

A programme you can afford for five years is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome here, and price is only one of the reasons people discontinue — tolerability, supply interruption and administrative friction account for the rest.

What a longer horizon costs

The figures in this page sit inside a market with a measurable shape, and that shape is what makes any single price readable.

Questions this page answers

What is the cheapest verified GLP-1 programme?

NexLife at $119 a month for semaglutide and $139 for tirzepatide on its 12-month plan, both at standard therapeutic dosing and first-party verified September 4, 2026. Month-to-month, NexLife is $139 and $169; Oak Longevity ($133, flat, no membership) is the next-cheapest semaglutide programme.

Are compounded GLP-1 medicines FDA-approved?

No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.

Why do the same programmes quote two different prices?

Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We rank on the month-to-month figure and state the prepaid rate separately, since a rate requiring a year's commitment is not the same offer.

Where do these prices come from?

Each is read from the programme's own published pricing page and carries its capture date. The full set of 24 standard-dose records is at /api/prices.json with molecule and dose class on every record.